MX2010007703A - Derivados de bifeprunox. - Google Patents

Derivados de bifeprunox.

Info

Publication number
MX2010007703A
MX2010007703A MX2010007703A MX2010007703A MX2010007703A MX 2010007703 A MX2010007703 A MX 2010007703A MX 2010007703 A MX2010007703 A MX 2010007703A MX 2010007703 A MX2010007703 A MX 2010007703A MX 2010007703 A MX2010007703 A MX 2010007703A
Authority
MX
Mexico
Prior art keywords
dopamine
bifeprunox
derivatives
oso3h
agonistic effects
Prior art date
Application number
MX2010007703A
Other languages
English (en)
Inventor
Herman H Van Stuivenberg
Gerrit A Barf
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of MX2010007703A publication Critical patent/MX2010007703A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a derivados de bifeprunox de fórmula (I) (ver fórmula I) en donde R1 es un sustituyente seleccionado de 3-OH, 4-OH, 3-OSO3H y 4- OSO3H; R2 es H; o un N-óxido o una sal, un solvato o hidrato farmacéuticamente aceptable de los mismos, que son ligandos potentes para el receptor de dopamina D2, presentando fuertes efectos agonistas respecto a la dopamina D2 parciales con un porcentaje de agonismo significativamente más alto que bifeprunox; los compuestos de la invención se pueden usar en el tratamiento, alivio o prevención de enfermedades y condiciones mediadas por los receptores de dopamina D2 que requieren efectos agonistas respecto a la dopamina D2.
MX2010007703A 2008-01-15 2009-01-14 Derivados de bifeprunox. MX2010007703A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2109008P 2008-01-15 2008-01-15
EP08150282 2008-01-15
PCT/EP2009/050336 WO2009090177A1 (en) 2008-01-15 2009-01-14 Bifeprunox derivatives

Publications (1)

Publication Number Publication Date
MX2010007703A true MX2010007703A (es) 2010-09-14

Family

ID=39434253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007703A MX2010007703A (es) 2008-01-15 2009-01-14 Derivados de bifeprunox.

Country Status (9)

Country Link
US (1) US20110105523A1 (es)
EP (1) EP2234990A1 (es)
JP (1) JP2011509969A (es)
CN (1) CN101918382A (es)
AU (1) AU2009204851A1 (es)
CA (1) CA2711520A1 (es)
MX (1) MX2010007703A (es)
RU (1) RU2010133980A (es)
WO (1) WO2009090177A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114246869A (zh) * 2022-01-18 2022-03-29 万宜合药业(海南)有限责任公司 联苯芦诺及其衍生物的抗肿瘤活性和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69736704T2 (de) * 1996-03-29 2007-09-13 Duphar International Research B.V. Piperazin- und piperidin- derivate
HUP0302016A2 (hu) * 2000-05-12 2003-09-29 Solvay Pharmaceuticals B.V. Piperazin és piperidinvegyületek, ezeket tartalmazó gyógyászati készítmények, eljárás elżállításukra és alkalmazásuk
MX2007006756A (es) * 2004-12-07 2007-11-09 Solvay Pharm Bv Fenilpiperazinas con una afinidad combinada para receptores de dopamina-d2 y sitios de reabsorcion de serotonina.
RU2394821C2 (ru) * 2005-08-22 2010-07-20 Солвей Фармасьютикал Б.В. N-оксиды как пролекарства производных пиперазина и пиперидина

Also Published As

Publication number Publication date
JP2011509969A (ja) 2011-03-31
AU2009204851A1 (en) 2009-07-23
EP2234990A1 (en) 2010-10-06
RU2010133980A (ru) 2012-02-27
US20110105523A1 (en) 2011-05-05
CA2711520A1 (en) 2009-07-23
WO2009090177A1 (en) 2009-07-23
CN101918382A (zh) 2010-12-15

Similar Documents

Publication Publication Date Title
MX2009005252A (es) Aminopirrolidinas como antagonistas del receptor de quimiocina.
PH12015502524B1 (en) New somatostatin receptor subtype 4 (sstr4) agonists
MY159615A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
MX2009000531A (es) Derivados heterociclicos fusionados y metodos de uso.
GEP20135925B (en) Inhibitors of hedgehog pathway
UA99882C2 (uk) Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
MX2009007200A (es) Indazoles sustituidos con amida como inhibidores de poli(adp-ribosa)polimerasa (parp).
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
PH12013502616A1 (en) Cyclopropyl amide derivatives 978
PH12016500394A1 (en) Polymorphic form of pyrrole derivative and intermediate thereof
MX2016004406A (es) Derivados de 1,4-ciclohexilamina y proceso para la preparacion de los mismos.
MY165113A (en) Piperidinone carboxamide azaindane cgrp receptor antagonists
MX2013000362A (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
NZ746950A (en) Heterocyclic gpr119 agonist compounds
IN2012DN02556A (es)
MY147789A (en) Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MY150774A (en) Isoquinoline derivative
MX2010002900A (es) Derivados heterociclicos triciclicos.
NZ714747A (en) Compounds of ‘3-(5-substituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester’, process and applications thereof
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MX2010007703A (es) Derivados de bifeprunox.
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.
MX2009003728A (es) Nuevos derivados de alcaloides de isocarbostirilo que tienen actividades anti-proliferativas y anti-migratorias.
MX2010011767A (es) Derivados de benzocicloheptano y benzoxepina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal